BioInvent International AB (publ)
OTC: BOVNF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Martin Welschof
- Employees
- 114
- Headquarters
- Lund, Sweden
- IPO year
- 2013
- Market cap
- $216.4M
- Website
- https://www.bioinvent.com
Loading BOVNF…
Loading profile data…Frequently asked questions about BOVNF
What does BioInvent International AB (publ) (BOVNF) do?
BioInvent International AB (publ) is a clinical-stage biotechnology company primarily focused on identifying, exploring, and engineering immunomodulatory antibodies to combat various forms of cancer. The company's activities extend globally, reaching markets in Sweden, across Europe, the United States, Japan, and other international regions. Its...
Where does BOVNF trade?
BioInvent International AB (publ) (BOVNF) trades on the Other OTC.
What sector is BOVNF in?
BioInvent International AB (publ) (BOVNF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of BioInvent International AB (publ)?
Martin Welschof is the chief executive officer of BioInvent International AB (publ) (BOVNF).
Where is BioInvent International AB (publ) headquartered?
BioInvent International AB (publ) is headquartered in Sweden.
Does BOVNF pay a dividend?
BioInvent International AB (publ) (BOVNF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did BOVNF go public?
BioInvent International AB (publ) (BOVNF) completed its initial public offering in 2013.